Insulet price target raised to $324 from $304 at Canaccord

Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported solid Q4 results and management’s FY25 guidance was generally in line with expectations, but investors were focused on the US Omnipod revenue guidance, which seems conservative. Canaccord still feels strong conviction in their thesis that Insulet has the best set up to capitalize on the T2D population given its form factor, distribution channel (pharmacy), and having the first IFU to market to this highly underpenetrated population.